中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2012年
8期
672-676
,共5页
曹华%许琨%王鹏举%姜国忠%高冬玲%王继伟%曹风雨%王尧河
曹華%許琨%王鵬舉%薑國忠%高鼕玲%王繼偉%曹風雨%王堯河
조화%허곤%왕붕거%강국충%고동령%왕계위%조풍우%왕요하
鼻咽肿瘤%腺病毒科%溶瘤病毒疗法%细胞系,肿瘤
鼻嚥腫瘤%腺病毒科%溶瘤病毒療法%細胞繫,腫瘤
비인종류%선병독과%용류병독요법%세포계,종류
Nasopharyngeal neoplasms%Adenoviridae%Oncolytic virotherapy%Cell line,tumor
目的 探讨新型溶肿瘤腺病毒Ad-TD-RFP对人鼻咽癌细胞C666-1的体内外治疗作用.方法 用细胞毒性检测法(MTS法)测定溶肿瘤腺病毒Ad-TD-RFP和对照病毒dl1520对鼻咽癌细胞C666-1的杀伤作用；半数组织培养感染剂量(TCID50)法检测Ad-TD-RFP和dl1520不同时间点(24 h、48 h、72 h、96 h)在鼻咽癌细胞C666-1中的复制能力；人鼻咽癌细胞C666-1 BALB/c裸鼠皮下成瘤,检测Ad-TD-RFP和dl1520对肿瘤大小的影响.结果 新型溶肿瘤腺病毒Ad-TD-RFP和对照病毒dl1520对鼻咽癌细胞C666-1的50％最大效应浓度(EC.)分别为(107.6±3.2) pt/细胞和(174.1±4.0) pt/细胞,差异有统计学意义(t=22.6,P＜0.001).在鼻咽癌细胞C666-1中在不同时间点(24h、48 h、72 h、96 h)Ad-TD-RFP是dl1520复制能力的3～14倍,差异有统计学意义(t值分别为33.6、23.4、20.8和17.3,P值均＜0.001).磷酸盐缓冲液组、dl1520治疗组和Ad-TD-RFP治疗组在治疗67 d后,移植瘤平均体积分别约为(1765.5±713.9)mm3、(1036.9±623.8)mm3、(420.8±238.7 )mm3,三组相比差异有统计学意义(F=12.0,P＜0.05).结论 新一代溶肿瘤腺病毒Ad-TD-RFP在体内外对鼻咽癌细胞C666-1有很好的治疗效果,为将来鼻咽癌病毒基因治疗提供一定的实验基础.
目的 探討新型溶腫瘤腺病毒Ad-TD-RFP對人鼻嚥癌細胞C666-1的體內外治療作用.方法 用細胞毒性檢測法(MTS法)測定溶腫瘤腺病毒Ad-TD-RFP和對照病毒dl1520對鼻嚥癌細胞C666-1的殺傷作用；半數組織培養感染劑量(TCID50)法檢測Ad-TD-RFP和dl1520不同時間點(24 h、48 h、72 h、96 h)在鼻嚥癌細胞C666-1中的複製能力；人鼻嚥癌細胞C666-1 BALB/c裸鼠皮下成瘤,檢測Ad-TD-RFP和dl1520對腫瘤大小的影響.結果 新型溶腫瘤腺病毒Ad-TD-RFP和對照病毒dl1520對鼻嚥癌細胞C666-1的50％最大效應濃度(EC.)分彆為(107.6±3.2) pt/細胞和(174.1±4.0) pt/細胞,差異有統計學意義(t=22.6,P＜0.001).在鼻嚥癌細胞C666-1中在不同時間點(24h、48 h、72 h、96 h)Ad-TD-RFP是dl1520複製能力的3～14倍,差異有統計學意義(t值分彆為33.6、23.4、20.8和17.3,P值均＜0.001).燐痠鹽緩遲液組、dl1520治療組和Ad-TD-RFP治療組在治療67 d後,移植瘤平均體積分彆約為(1765.5±713.9)mm3、(1036.9±623.8)mm3、(420.8±238.7 )mm3,三組相比差異有統計學意義(F=12.0,P＜0.05).結論 新一代溶腫瘤腺病毒Ad-TD-RFP在體內外對鼻嚥癌細胞C666-1有很好的治療效果,為將來鼻嚥癌病毒基因治療提供一定的實驗基礎.
목적 탐토신형용종류선병독Ad-TD-RFP대인비인암세포C666-1적체내외치료작용.방법 용세포독성검측법(MTS법)측정용종류선병독Ad-TD-RFP화대조병독dl1520대비인암세포C666-1적살상작용；반수조직배양감염제량(TCID50)법검측Ad-TD-RFP화dl1520불동시간점(24 h、48 h、72 h、96 h)재비인암세포C666-1중적복제능력；인비인암세포C666-1 BALB/c라서피하성류,검측Ad-TD-RFP화dl1520대종류대소적영향.결과 신형용종류선병독Ad-TD-RFP화대조병독dl1520대비인암세포C666-1적50％최대효응농도(EC.)분별위(107.6±3.2) pt/세포화(174.1±4.0) pt/세포,차이유통계학의의(t=22.6,P＜0.001).재비인암세포C666-1중재불동시간점(24h、48 h、72 h、96 h)Ad-TD-RFP시dl1520복제능력적3～14배,차이유통계학의의(t치분별위33.6、23.4、20.8화17.3,P치균＜0.001).린산염완충액조、dl1520치료조화Ad-TD-RFP치료조재치료67 d후,이식류평균체적분별약위(1765.5±713.9)mm3、(1036.9±623.8)mm3、(420.8±238.7 )mm3,삼조상비차이유통계학의의(F=12.0,P＜0.05).결론 신일대용종류선병독Ad-TD-RFP재체내외대비인암세포C666-1유흔호적치료효과,위장래비인암병독기인치료제공일정적실험기출.
Objective To evaluat the antitumor efficacy of Ad-TD-RFP for human nasopharyngeal carcinoma cells ( C666-1 ) in vitro and in vivo.Methods The oncolytic effects of Ad-TD-RFP and control virus dl11520 on C666-1 cells were determined by cytotoxicity assay (MTS assay).Viral replication of AdTD-RFP and dl11520 was detected at different time points (24 h,48 h,72 h and 96 h) by tissue culture infective dose (TCID50) in C666-1 cells implanted subcutaneously into the flank in each of BALB/c nude mice.The xenografts were injected intratumorally with Ad-TD-RFP or dl1520 to investigate their effects on tumor growth.Results The concentration for 50％ of maximal effect ( EC50 ) values of Ad-TD-RFP and dl1520 were ( 107.6 ±3.2) pt/cell and ( 174.1 ±4.0) pt/cell,respectively (t =22.6,P ＜0.001 ).The Ad-TD-RFP replication was 3 - 14 folds more than dl1520 replication at four time points (24 h,48 h,72 h and 96 h) in C666-1 cells (t values were 33.6,23.4,20.8 and 17.3,respectively,P＜0.001).The average tumor volumes of PBS group,dl1520 group and Ad-TD-RFP group were ( 1765.5 ± 713.9 ) mm3,( 1036.9 ± 623.8 ) mm3,and (420.8 ± 238.7 )mm3,respectively ( F =1 2.0,P ＜ 0.05 ) on day 67 after treatment.Conclusions The antitumour efficacy of the novel oncolytic adenovirus Ad-TD-RFP for human nasopharyngeal carcinoma C666-1 cells is superior to that of dl1520 in vitro and in vivo.The outcome of this study provides an experimental basis for the tratment of human nasopharyngeal carcinoma by viral gere therapy.
